Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium lactis Bl-04
- Development stage
- Phase 2
- Lead developer
- International Flavors & Fragrances
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium lactis Bl-04 is a specific probiotic strain of *Bifidobacterium animalis subsp. lactis* that has been extensively studied for its role in supporting immune health. It is primarily used in dietary supplements and functional foods to reduce the risk and duration of upper respiratory tract infections and to alleviate symptoms of seasonal allergies, such as birch pollen allergy. The strain was originally developed by Danisco and is now part of the IFF (International Flavors & Fragrances) portfolio under the HOWARU brand. Bl-04 is thought to work by modulating the gut-associated lymphoid tissue, thereby influencing systemic immune responses and improving the body's resistance to viral challenges like the common cold.
- Brand names
- HOWARU Protect Adult
- Other names
- Bifidobacterium animalis subsp. lactis Bl-04B. lactis Bl-04
Beyond the preview
Go deeper on bifidobacterium lactis Bl-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium lactis Bl-04.